Last updated: August 19, 2026, with current FDA safety information, ClinicalTrials.gov records, scientific references, reconstitution calculations and updated evidence on GHK-Cu dosing.
Quick Answer: Is There an Established Human GHK-Cu Injection Dosage?
No universally established, FDA-approved human injection dosage for GHK-Cu currently exists. GHK-Cu has a long research history as a naturally occurring copper-binding peptide, and topical GHK-Cu has been studied in limited human skin research. That evidence should not be treated as proof of a standard injectable GHK-Cu peptide injection dosage chart.
The most important distinction is route. Endogenous GHK-Cu biology, topical skincare research, ex-vivo skin penetration studies, cell culture work, animal wound-healing research and compounded injectable products are different evidence categories. A dose, concentration or percentage from one category does not automatically transfer to another.
The FDA currently lists GHK-Cu for injectable routes of administration among bulk substances for which compounded injectable drugs may present significant safety risks. FDA notes limited human safety data and potential concerns involving immunogenicity, aggregation and peptide-related impurities (FDA). That does not prove every GHK-Cu product is dangerous, but it does mean an injectable protocol should not be presented as an established medical standard.
The calculator and tables below explain vial strength, mg-to-mcg conversion, concentration per mL, volume for a selected research amount and U-100 syringe-unit math. These calculations convert quantities; they do not determine what amount a person should use.
What Is GHK-Cu?
GHK is glycyl-L-histidyl-L-lysine, a naturally occurring tripeptide. GHK-Cu is the copper(II)-complexed form, often written as glycyl-L-histidyl-L-lysine-Cu(2+) or copper tripeptide-1. GHK has been reported in human plasma, saliva and urine, and it can bind copper ions through its amino acid sequence.
Research has examined GHK and GHK-Cu in extracellular-matrix remodeling, collagen-related processes, wound biology, inflammatory signaling, angiogenesis, skin aging and tissue-repair models. Early fibroblast research from Maquart and colleagues reported that GHK-Cu stimulated collagen synthesis in cultured fibroblasts at very low molar concentrations (Maquart et al.). Later work found effects on matrix metalloproteinase-2 and tissue inhibitors of metalloproteinases in dermal fibroblast cultures (Simeon et al.).
These mechanistic findings help explain why GHK-Cu is discussed in skin and wound-healing research, but they do not establish an injectable human dosage. Cell-culture concentrations, topical percentages and compounded vial strengths are different units serving different purposes.
Topical vs Injectable GHK-Cu: What Has Actually Been Studied?
Topical GHK-Cu has some human skin evidence, but it is limited. A small randomized study after CO2 laser resurfacing enrolled 13 completing patients. Objective computer analysis and blinded evaluations did not find significant differences in erythema, wrinkles or overall skin quality between the GHK-Cu skincare group and the comparison group, although patient-reported overall skin-quality satisfaction differed (Miller et al.).
A 2025 PubMed-indexed review on topically applied GHK noted that GHK-Cu and related peptides are widely used in cosmetic products, but published information on skin permeability, effectiveness and physicochemical properties remains insufficient. The review specifically noted a surprising absence of clinical studies using GHK-Cu and Pal-GHK despite extensive cellular research (Mortazavi et al.).
Microneedle and skin-delivery studies are not injection-dosing trials. Skin penetration work has tested methods to improve delivery through skin barriers, including microneedle pretreatment and peptide modifications. Those studies can help explain formulation and penetration challenges, but they do not demonstrate a consumer injectable dosing regimen.
Injectable compounded GHK-Cu has a different evidence and safety profile. Topical, ex-vivo, cell and animal findings should not be extrapolated into a clinically validated injectable GHK-Cu dosage protocol.
GHK-Cu Dosage Chart: What the Numbers Actually Mean
A useful GHK-Cu dosage chart should identify the source and meaning of each number. A topical 0.1% gel in a clinical trial, a 100 mg research vial, a fibroblast concentration and an internet injection protocol are not interchangeable.
| Context | Amount or concentration reported | Route | Evidence type | What it proves | What it does not prove |
|---|---|---|---|---|---|
| Endogenous GHK/GHK-Cu biology | Physiological peptide present in human fluids | Natural biology | Human biochemical literature and reviews | GHK is a naturally occurring copper-binding tripeptide | Does not define an injected dose |
| Fibroblast/collagen research | Low molar cell-culture concentrations | In vitro | Cell research | GHK-Cu can affect collagen and matrix-remodeling markers in cultured cells | Does not establish human injection amount, frequency or cycle length |
| CO2 laser resurfacing study | GHK-Cu-containing skincare regimen | Topical | Small randomized human study | Patient satisfaction differed; objective measures did not show clear group differences | Does not support injectable dosing |
| NCT07437586 wound-healing trial | 0.1% w/w gel, about 0.5 g once daily for 14 days | Topical | Phase 2 recruiting trial; no posted results | Shows a current controlled topical research design | Does not prove efficacy yet and does not apply to injection dosing |
| 5 mg, 50 mg and 100 mg vials | Total amount in the vial | Product/research material | Calculator input | Defines how much material is available for concentration math | Vial size is not the same as dose |
| Community or clinic injection numbers | Often expressed as mcg per injection or mg per week | Injectable | Not an established clinical dosing standard | Shows what some non-standard protocols discuss | Does not prove safety, efficacy or an evidence-based recommendation |
GHK-Cu Dosage Calculator: Concentration and Measurement Math
A GHK-Cu dosage calculator is best understood as a concentration calculator. It answers questions like “How many mcg are in each mL?” and “How many U-100 syringe units correspond to a selected amount?” It does not determine whether that selected amount is appropriate.
You can also use the Peptides Unleashed peptide calculator for general peptide concentration math. Keep the same evidence boundary in mind: calculator output is measurement math, not medical advice.
Basic GHK-Cu calculator formulas
- Convert vial strength: 1 mg = 1,000 mcg.
- Concentration: vial amount in mcg ÷ diluent volume in mL = mcg/mL.
- Selected amount to volume: selected amount in mcg ÷ concentration in mcg/mL = mL to draw.
- U-100 syringe math: mL x 100 = U-100 syringe units.
Example 1: a 5 mg vial contains 5,000 mcg. If mixed with 2 mL diluent, concentration is 2,500 mcg/mL. A selected 250 mcg research amount equals 0.1 mL, or 10 units on a U-100 syringe.
Example 2: a 100 mg vial contains 100,000 mcg. At a hypothetical final volume of 10 mL, concentration is 10,000 mcg/mL. A selected 500 mcg research amount equals 0.05 mL, or 5 U-100 units. This example is arithmetic only.
GHK-Cu 100 mg Dosage Calculator and Reconstitution Math
A 100 mg GHK-Cu vial contains 100,000 mcg total material. It is not a 100 mg dose. Changing the amount of diluent changes concentration, not the total GHK-Cu in the vial.
Readers comparing product formats may encounter a standalone Fitaminos GHK-Cu 100 mg research product. That link is commercial product context only; scientific and safety claims on this page are supported by the research and regulatory sources cited here, not by a product page.
| 100 mg vial + diluent | mg/mL | mcg/mL | mcg per 0.01 mL | U-100 meaning | 500 mcg example |
|---|---|---|---|---|---|
| 100 mg + 5 mL | 20 mg/mL | 20,000 mcg/mL | 200 mcg | 1 unit = 200 mcg | 0.025 mL / 2.5 units |
| 100 mg + 10 mL | 10 mg/mL | 10,000 mcg/mL | 100 mcg | 1 unit = 100 mcg | 0.05 mL / 5 units |
| 100 mg + 20 mL | 5 mg/mL | 5,000 mcg/mL | 50 mcg | 1 unit = 50 mcg | 0.10 mL / 10 units |
These are mathematical concentration examples. Actual vial capacity, diluent volume and product-specific handling instructions vary.
The table is designed for concentration and measurement. It should not be read as a GHK-Cu peptide injection dosage protocol, female dose, skin dose, hair dose or anti-aging dose.
GHK-Cu 50 mg and 5 mg Calculator Examples
Vial sizes vary. A 5 mg vial can be useful for small-volume examples, while 50 mg and 100 mg formats require more careful concentration math.
GHK-Cu 5 mg Reconstitution Calculator
| 5 mg vial + diluent | Concentration | 100 mcg equals | 250 mcg equals | 500 mcg equals |
|---|---|---|---|---|
| 5 mg + 1 mL | 5,000 mcg/mL | 0.02 mL / 2 units | 0.05 mL / 5 units | 0.10 mL / 10 units |
| 5 mg + 2 mL | 2,500 mcg/mL | 0.04 mL / 4 units | 0.10 mL / 10 units | 0.20 mL / 20 units |
These are mathematical concentration examples. Actual vial capacity, diluent volume and product-specific handling instructions vary.
5 mg vs 50 mg vs 100 mg GHK-Cu Vials
| Vial strength | Total mcg | At a hypothetical final volume of 10 mL | Key point |
|---|---|---|---|
| 5 mg | 5,000 mcg | 500 mcg/mL | Lower total amount; easier small examples |
| 50 mg | 50,000 mcg | 5,000 mcg/mL | Ten times the total amount of a 5 mg vial |
| 100 mg | 100,000 mcg | 10,000 mcg/mL | Vial strength is not the same as dose |
These are mathematical concentration examples. Actual vial capacity, diluent volume and product-specific handling instructions vary.
Adding more diluent makes the liquid less concentrated. It does not change the amount of GHK-Cu in the vial.
GHK-Cu Dosage for Women: Is There a Female-Specific Dose?
No validated female-specific injectable GHK-Cu dosage has been established. Some topical cosmetic studies have included women, and skin biology can differ by sex, age, hormones, pregnancy status and life stage. Those facts do not create a separate injectable dose chart for women.
The topical eye-area and facial-skin studies summarized in reviews involved female participants with photodamage, but these were topical cosmetic contexts and are not the same as subcutaneous or intramuscular injection protocols (Mortazavi et al.). Pregnancy and breastfeeding are separate safety considerations because injectable GHK-Cu human safety data are limited and compounded injectable products are not FDA-approved.
For women, the calculator math is unchanged: vial strength, diluent volume and selected amount determine concentration and draw volume. Evidence has not established that women require a specific lower or higher injectable amount.
GHK-Cu Dosage Per Day vs Per Week
Published evidence does not establish a standard GHK-Cu injection dose per day or per week. Daily and weekly injection schedules discussed online should be treated as community or clinic-style protocols unless tied to a specific human study using that route and amount.
Topical research can include daily application, but that is route-specific. The current Phase 2 wound-healing trial uses 0.1% w/w topical GHK-Cu gel once daily to assigned punch-biopsy wounds for 14 days, with no results posted as of this update (NCT07437586). That does not establish a daily injectable GHK-Cu dose.
Calculator math can convert a chosen research amount into a daily or weekly total. It cannot determine whether the chosen amount is appropriate for a person or outcome.
GHK-Cu Dosing Protocol, Frequency and Cycle Length
A GHK-Cu dosing protocol should state its evidence category: topical human study, current clinical trial, cell culture, animal model, ex-vivo penetration study, or non-standard clinic/community practice. Study duration is not automatically a treatment recommendation.
The CO2 laser-resurfacing study assessed outcomes over 12 weeks after a topical skincare regimen. The current Phase 2 wound model applies topical gel for 14 days and follows wounds and scars over later visits. Cell and animal studies use their own experimental timelines. None of these establishes a universal 4-week, 8-week or 16-week injectable cycle.
For injectable compounded GHK-Cu, the evidence and regulatory limitations are the central issue. Frequency and cycle length should not be presented as settled without human route-specific data.
GHK-Cu for Skin and Collagen: What the Research Shows
GHK-Cu has the strongest research rationale in skin and connective-tissue biology, but the evidence is mixed by route and study type. In fibroblast cultures, GHK-Cu stimulated collagen synthesis and matrix-remodeling markers (Maquart et al.; Simeon et al.). Reviews also describe gene-expression and tissue-remodeling mechanisms (Pickart and Margolina).
Human topical cosmetic evidence is more limited than marketing often suggests. The small post-laser study did not show clear objective superiority for erythema, wrinkles or overall skin quality, although patient satisfaction differed. Reviews cite older topical studies reporting changes in skin density, thickness or wrinkle appearance, but the 2025 review emphasizes that clinical studies remain surprisingly sparse.
GHK-Cu for Hair: What the Research Shows
GHK-Cu is often discussed for hair because copper peptides have been studied in skin and follicle biology. However, cell and cosmetic evidence should not be turned into a claim that a specific injected amount produces hair regrowth.
Available literature is better described as mechanistic and indirect: GHK-Cu may influence tissue-remodeling, inflammatory and repair pathways relevant to skin and follicles, but robust human trials defining a GHK-Cu hair-loss dose, route, frequency and expected regrowth timeline are not established. Hair-related claims should therefore be framed as research interest, not a guaranteed outcome.
GHK-Cu for Wound Healing and Tissue Repair
Wound healing is one of the most relevant research areas for GHK-Cu. Laboratory and animal work has examined collagen, glycosaminoglycans, immune-cell signaling, angiogenesis and tissue repair. The current Phase 2 topical trial is important because it uses a controlled split-wound model in healthy adults with standardized 5 mm punch-biopsy wounds (NCT07437586).
The trial is topical: 0.1% w/w GHK-Cu gel, approximately 0.5 g, once daily to the assigned wound for 14 days. It is recruiting, with no posted results as of this update. It should not be used as evidence for an injectable 0.1% product or an injectable dosage schedule.
Current Human GHK-Cu Clinical Research
The most relevant current human trial is NCT07437586, Topical GHK-Cu Gel for Acute Skin Wound Healing. It is a Phase 2, randomized, double-blind, vehicle-controlled split-wound study in healthy adults. The study began in 2026 and is recruiting as of the ClinicalTrials.gov record reviewed for this update.
Participants receive two small punch-biopsy wounds on the upper arm. One wound is assigned to topical GHK-Cu gel and the other to vehicle gel under standardized dressings. The experimental product is a 0.1% w/w topical gel applied once daily for 14 days, with wound healing assessed across follow-up visits. No results are currently posted (ClinicalTrials.gov).
This trial may eventually improve human evidence for topical GHK-Cu wound healing. It does not validate injectable GHK-Cu dosing.
GHK-Cu Storage and Stability
For the general principles behind the conditions below, see how to store peptides.
GHK-Cu storage depends on formulation, concentration, diluent, sterility, vial or container, temperature, light exposure and product-specific instructions. Lyophilized research materials are often protected from heat, light and moisture. Reconstituted solutions are commonly handled cold, but a universal post-reconstitution shelf life should not be assumed.
Blanket post-reconstitution shelf-life claims are too broad. Product-specific manufacturer documentation, pharmacy instructions, certificate of analysis, sterility controls and research protocol instructions are more relevant than a generic internet timeline.
For topical cosmetic products, stability is a formulation issue. For injectable compounded products, sterility, aggregation, impurities and route-specific risk become more important.
GHK-Cu Safety, Side Effects and FDA Status
Injectable GHK-Cu should be discussed cautiously because human safety data are limited. FDA identifies GHK-Cu for injectable routes among nominated/withdrawn bulk substances for which compounded injectable products may pose immunogenicity risk due to potential aggregation and peptide-related impurities (FDA).
Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. That is separate from topical cosmetic products that contain copper peptide ingredients and are marketed under cosmetic rules.
Possible practical concerns include local irritation, redness, swelling, contamination risk, dosing errors caused by concentrated vials, product impurities, uncertain long-term exposure and uncertainty in pregnancy, breastfeeding or complex medical conditions. Topical formulation compatibility, such as whether to combine copper peptides with acidic skincare products, is a formulation issue and should not be mixed with injectable dosing advice.
GHK-Cu Research Evidence Table
| Study/source | Model/population | Route | What was tested | Main finding | Major limitation |
|---|---|---|---|---|---|
| Pickart, Freedman et al., Nature, 1980 | Plasma tripeptide/copper biology | Biochemical research | Growth-modulating plasma tripeptide and copper binding | Helped establish GHK as a copper-binding biological peptide | Not a clinical dosing study |
| Maquart et al., FEBS Letters, 1988 | Fibroblast cultures | In vitro | GHK-Cu effects on collagen synthesis | Stimulated collagen synthesis in cultured fibroblasts | Cell concentrations do not translate to human injection dosing |
| Simeon et al., Life Sciences, 2000 | Dermal fibroblast cultures | In vitro | MMP-2, TIMP-1 and TIMP-2 expression | Supported a role in extracellular-matrix remodeling | Not a human treatment trial |
| Miller et al., 2006 | 13 patients after CO2 laser resurfacing | Topical skincare | GHK-Cu-containing regimen versus comparison regimen | No objective group difference for erythema, wrinkles or overall skin quality; patient satisfaction differed | Small study; topical route only |
| Li et al., Pharm Res, 2015 | Human dermatomed skin/permeation model | Microneedle-assisted skin delivery | GHK-Cu permeation after microneedle pretreatment | Studied delivery through skin barriers | Not an injectable dosing protocol |
| Mortazavi et al., 2025 review | Topical GHK/GHK-Cu literature | Topical and skin-permeation review | Anti-wrinkle evidence and permeation limitations | Found cellular support but insufficient clinical/permeability data | Review; not an injectable dose-finding trial |
| NCT07437586 | Healthy adults with standardized punch-biopsy wounds | Topical | 0.1% w/w GHK-Cu gel once daily for 14 days | Recruiting Phase 2 trial; no results posted | Topical route; no efficacy results yet |
| FDA safety-risk page | Compounded injectable products | Injectable | Bulk substance safety considerations | FDA notes limited human safety data and potential immunogenicity/impurity concerns | Regulatory safety assessment, not proof of efficacy or harm in every case |
GHK-Cu Dosage FAQ
Is there an established GHK-Cu injection dosage chart?
No established, FDA-approved GHK-Cu injection dosage chart exists. Published evidence includes endogenous peptide biology, topical human studies, skin-delivery research, cell culture and animal work. Those sources do not define a validated injectable dose, frequency or cycle length for humans.
How does a GHK-Cu dosage calculator work?
A GHK-Cu dosage calculator converts vial strength and diluent volume into concentration. First convert mg to mcg, then divide by mL of diluent to get mcg/mL. Divide a selected research amount by that concentration to get mL, then multiply by 100 for U-100 units.
How do you calculate a 100 mg GHK-Cu vial?
A 100 mg vial contains 100,000 mcg. At a hypothetical final volume of 10 mL, the concentration is 10,000 mcg/mL. On a U-100 syringe, 0.01 mL equals 1 unit, so each unit would contain 100 mcg at that concentration.
Is a 100 mg vial the same as a 100 mg dose?
No. A 100 mg vial describes the total amount of GHK-Cu in the vial. Dose or selected research amount is a separate concept. Adding diluent changes concentration per mL, not the total material in the vial.
Is there a different GHK-Cu dosage for women?
No validated female-specific injectable GHK-Cu dosage has been established. Some topical cosmetic studies include women, but topical evidence does not create an injectable female dose chart. Pregnancy, breastfeeding and hormone-related considerations increase the need for caution because injectable human safety data are limited.
What is the GHK-Cu dosage per day?
There is no evidence-based standard GHK-Cu injection dose per day. Topical research may use daily application, such as the current 0.1% topical gel wound-healing trial, but that does not establish a daily injectable dose.
What is a GHK-Cu dosing protocol?
A credible protocol should specify route, concentration, population, duration and evidence source. A topical clinical-trial protocol is different from a cell-culture experiment or a community injection schedule. For injectable GHK-Cu, a validated human protocol has not been established.
How do you calculate GHK-Cu after reconstitution?
Convert the vial amount to mcg and divide by the diluent volume. For example, 5 mg equals 5,000 mcg. Mixed with 2 mL, that equals 2,500 mcg/mL. A selected 250 mcg amount would be 0.1 mL, or 10 U-100 units.
How much bacteriostatic water is used for GHK-Cu?
No universal diluent volume is established for all GHK-Cu products. Common calculator examples use 1 mL, 2 mL, 5 mL, 10 mL or 20 mL because they create easy concentrations. Product-specific instructions or a research protocol should control handling decisions.
What is the difference between 5 mg, 50 mg and 100 mg GHK-Cu?
The difference is total material. A 5 mg vial contains 5,000 mcg, a 50 mg vial contains 50,000 mcg and a 100 mg vial contains 100,000 mcg. Larger vials usually require more attention to concentration math.
Does adding more bacteriostatic water change the amount of GHK-Cu?
No. Adding more diluent lowers concentration per mL but does not change total GHK-Cu in the vial. A 100 mg vial still contains 100 mg whether mixed with 5 mL, 10 mL or 20 mL.
What human evidence exists for injectable GHK-Cu?
Human evidence for injectable GHK-Cu dosing is limited. FDA identifies compounded injectable GHK-Cu as a route-specific safety concern because of limited human safety data and potential immunogenicity, aggregation and peptide-related impurity issues.
What human evidence exists for topical GHK-Cu?
Topical GHK-Cu has limited human evidence. A small CO2 laser resurfacing study found no objective group difference in erythema, wrinkles or overall skin quality, although patient satisfaction differed. A current Phase 2 trial is studying 0.1% topical GHK-Cu gel for standardized acute wounds.
How should GHK-Cu be stored after reconstitution?
Storage depends on formulation, diluent, sterility, container, concentration, temperature and light exposure. There is no universal post-reconstitution shelf life that applies to every GHK-Cu product. Follow product-specific documentation, pharmacy instructions or the research protocol.
Is GHK-Cu FDA approved?
Compounded injectable GHK-Cu is not FDA-approved. FDA has identified injectable-route safety concerns for GHK-Cu among certain bulk substances, including limited human safety data and potential immunogenicity or impurity issues. Topical cosmetic products are a different regulatory category.
Scientific References
- Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. PubMed.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. FDA.
- ClinicalTrials.gov. Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586). ClinicalTrials.gov.
- Miller TR, Wagner JD, Baack BR, Eisbach K. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006. PubMed.
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts. 2025. PubMed.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988. PubMed.
- Simeon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences. 2000. PubMed.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. PubMed.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PubMed.
- Li H, Low YSJ, Chong HP, et al. Microneedle-mediated delivery of copper peptide through skin. Pharmaceutical Research. 2015. PubMed.
- Godet D, Marie PJ. Effects of the tripeptide glycyl-L-histidyl-L-lysine copper complex on osteoblastic cell spreading, attachment and phenotype. Cellular and Molecular Biology. 1995. PubMed.
Where to source GHK-Cu
Fit Aminos stocks research-grade GHK-Cu copper peptide.
We are affiliated with Fit Aminos and may earn from purchases made through this link.
